Strategic Mergers Following its merger with Sobi AB, CTI BioPharma is now positioned as a global biopharma entity focused on rare and debilitating diseases, presenting opportunities for international collaboration and market expansion.
Innovative Research Sobi's recent launch of a documentary on rare kidney diseases demonstrates its commitment to patient engagement and awareness, opening avenues for partnerships in patient education, advocacy, and caregiver support programs.
Pipeline Expansion The planned acquisition of Arthrosi Therapeutics for up to 1.5 billion USD significantly strengthens Sobi’s gout treatment portfolio, indicating potential sales opportunities in similar niche therapeutic areas and pipeline development collaborations.
Technological Integration Using advanced analytics and data visualization tools like IBM Cognos and Google Data Studio, Sobi shows a focus on data-driven decision-making, suggesting potential for partnerships in digital health solutions, analytics, and supply chain optimization.
Supply Chain Modernization Sobi's recent engagement with Kinaxis for supply chain orchestration reflects its emphasis on enhancing supply chain efficiency, which could be a prospect for innovative logistics, inventory management, and operational technology solutions.
$1M$10M
$1M
$10M$25MCTI BioPharma uses 8 technology products and services including IBM Cognos Analytics, Google Data Studio, Microsoft PowerPoint, and more. Explore CTI BioPharma's tech stack below.
| CTI BioPharma Email Formats | Percentage |
| FLast@ctibiopharma.com | 93% |
| Last@ctibiopharma.com | 5% |
| First.Last@ctibiopharma.com | 1% |
| FMiddleLast@ctibiopharma.com | 1% |
| First.Last@sobi.com | 98% |
| First.MiddleLast@sobi.com | 1% |
| First.Middle@sobi.com | 1% |
Biotechnology ResearchWashington, United States51-200 Employees
We have merged with Sobi AB creating a biopharma company positioned to provide innovative medicines that transform the lives of people with rare and debilitating diseases. Visit www.sobi.com to continue to learn more about our work. For more information on the acquisition, see our press release at: https://bit.ly/42XKW9M
Company Overview
Media & News
Funding & FinancialsCTI BioPharma has raised a total of $50M of funding over 8 rounds. Their latest funding round was raised on Aug 25, 2021 in the amount of $50M.
Funding & FinancialsCTI BioPharma has raised a total of $50M of funding over 8 rounds. Their latest funding round was raised on Aug 25, 2021 in the amount of $50M.
1-888-653-2347 
support@leadiq.com